Target Name: RAVER2
NCBI ID: G55225
Review Report on RAVER2 Target / Biomarker Content of Review Report on RAVER2 Target / Biomarker
RAVER2
Other Name(s): RAVER2 variant 2 | Ribonucleoprotein PTB-binding 2 | protein raver-2 | Ribonucleoprotein, PTB binding 2, transcript variant 1 | Ribonucleoprotein, PTB binding 2, transcript variant 2 | Protein raver-2 | ribonucleoprotein, PTB binding 2 | RAVR2_HUMAN | Ribonucleoprotein PTB-binding 2 isoform 1 | RAVER2 variant 1 | Ribonucleoprotein PTB-binding 2 (isoform 2) | KIAA1579

RAVER2: A Non-Coding RNA Molecule as A Potential Drug Target and Biomarker

Ravver2 (RAVER2) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and mental health conditions. Ravver2 is a key regulator of gene expression in many cell types and has been shown to play a role in a variety of cellular processes, including cell adhesion, migration, and survival.

The RAVER2 gene

The RAVER2 gene is located on chromosome 18q21 and has a length of approximately 2,100 nucleotides. It is a non-coding RNA molecule that is expressed in many different cell types, including tissues, organs, and fluids. The RAVER2 gene has been shown to play a role in regulating gene expression and has been associated with a number of different diseases.

The RAVER2 protein

The RAVER2 protein is a 280- amino acid protein that is expressed in many different cell types, including tissues, organs, and fluids. It is characterized by a number of conserved domains, including a N-terminal transmembrane domain, a catalytic domain, and a C-terminal T-loop. The RAVER2 protein is involved in a variety of cellular processes, including cell adhesion, migration, and survival.

The RAVER2-containing RNA molecules

Several studies have shown that the RAVER2 gene is involved in regulating gene expression in many different cell types. For example, studies have shown that the RAVER2 gene is involved in regulating the expression of genes involved in cell adhesion, migration, and survival. Additionally, the RAVER2 gene has been shown to play a role in regulating the expression of genes involved in inflammation and immune response.

The potential drug target

The potential drug target for Ravver2 is its role in regulating gene expression and its involvement in a variety of cellular processes. Because of its involvement in these processes, the RAVER2 protein is a potential drug target for a variety of diseases, including cancer, neurodegenerative diseases, and mental health conditions.

The RAVER2-based biomarker

The RAVER2 gene has also been shown to be involved in the regulation of gene expression in many different cell types, including cancer cells. This suggests that the RAVER2 protein may be a useful biomarker for cancer, particularly for those with aggressive or recurrent tumors. Additionally, the RAVER2 gene has been shown to be involved in the regulation of gene expression in neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. This suggests that the RAVER2 protein may be a useful biomarker for these conditions as well.

Conclusion

In conclusion, the RAVER2 gene is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for a variety of diseases, including cancer, neurodegenerative diseases, and mental health conditions. The RAVER2 protein is a 280- amino acid protein that is involved in a variety of cellular processes, including cell adhesion, migration, and survival. Further research is needed to fully understand the role of the RAVER2 gene and protein in these diseases and to develop effective treatments.

Protein Name: Ribonucleoprotein, PTB Binding 2

Functions: May bind single-stranded nucleic acids

The "RAVER2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RAVER2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

RAX | RAX2 | RB1 | RB1-DT | RB1CC1 | RBAK | RBAK-RBAKDN | RBAKDN | RBBP4 | RBBP4P2 | RBBP4P6 | RBBP5 | RBBP6 | RBBP7 | RBBP8 | RBBP8NL | RBBP9 | RBCK1 | RBFA | RBFOX1 | RBFOX2 | RBFOX3 | RBIS | RBKS | RBL1 | RBL2 | RBM10 | RBM11 | RBM12 | RBM12B | RBM14 | RBM14-RBM4 | RBM15 | RBM15-AS1 | RBM15B | RBM17 | RBM17P1 | RBM18 | RBM19 | RBM20 | RBM22 | RBM22P1 | RBM23 | RBM24 | RBM25 | RBM26 | RBM26-AS1 | RBM27 | RBM28 | RBM3 | RBM33 | RBM34 | RBM38 | RBM39 | RBM4 | RBM41 | RBM42 | RBM43 | RBM43P1 | RBM44 | RBM45 | RBM46 | RBM47 | RBM48 | RBM48P1 | RBM4B | RBM5 | RBM5-AS1 | RBM6 | RBM7 | RBM8A | RBMS1 | RBMS1P1 | RBMS2 | RBMS2P1 | RBMS3 | RBMS3-AS3 | RBMX | RBMX2 | RBMX2P1 | RBMXL1 | RBMXL2 | RBMXL3 | RBMY1A1 | RBMY1B | RBMY1D | RBMY1F | RBMY1J | RBMY2EP | RBMY2FP | RBP1 | RBP2 | RBP3 | RBP4 | RBP5 | RBP7 | RBPJ | RBPJL | RBPJP2 | RBPMS